Cialis Online

Lilly ICOS' Cialis(R) Makes Impressive Strides in First Six Months on the U.S. ED Treatment Market

Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation, new product Cialis challenges Viagra on the erectile dysfunction market. Research show that more and more urologists are prescribing Cialis instead of Viagra in new erectile dysfunction treatment initiations.
ImpactRx™ a market research firm (which tracks the habits of a panel of high prescribing physicians and may reflect emerging trends in doctors' offices today) show that Cialis represent 56% of the new erectile dysfunction treatment initiations by urologists in April compared with 23% Viagra (sidefil citrate) and 21 percent for Levitra® (vardenafil HCl).
In April almost 70% of men that switch to another erectile dysfunction treatment switched to Cialis. Following the information from ImpactRx on share of new prescriptions written in April by doctors changing their patients' ED treatment from one product to another.

Primary Care Physicians - New erectile dysfunction treatment prescription
Cialis 60%
Levitra 36%
Viagra 4%

Urologists - New erectile dysfunction treatment prescription
Cialis 69%
Levitra 26%
Viagra 5%

In an independent clinical test men affirmed that the first reason of switching to Cialis is the long lasting effect that Cialis have. The 36 hours effect and mild side effects explain why many man that are using oral treatments to switch to Cialis.
After the first month in the first quarter of 2004 Cialis achieved 108 millions in global sales. Over 2 millions from all over the world used Cialis to treat ED.
After the first month in the first quarter of 2004 Cialis achieved 108 millions in global sales. Over 2 millions from all over the world used Cialis to treat ED. Research show that urologist from all over the world started prescribing Cialis instead Viagra and Levitra.

Posted by CBlog at 7:56 AM